Type II cancer had gene mutations (e.g., TP53 and BRCA) and copy amplifications (e.g., MYC and CCNE1), which can cause cisplatin resistance (Brachova et al., 2013; Rojas et al., 2016; Singh et al., 2019; Gorski et al., 2020). This evidence concerns the gene TP53 and cancer.